Sensus Healthcare, Inc.
Sensus Healthcare is a medical device company headquartered in Boca Raton, Florida. It develops and sells devices using superficial radiation therapy, a low-energy X-ray technology for treating non-melanoma skin cancer and keloids. Its product line includes the SRT-100, SRT-100+ and SRT-100 Vision. As of December 31, 2025, Sensus had installed 955 units in 21 countries, primarily in the United States. Its customers include private dermatology practices and radiation oncologists in private and hospital settings, reached through a U.S. direct sales force and international dealers and distributors. Sensus also earns money from system service contracts, consumables and operational healthcare services. Its Sentinel program provides system coverage and installation, commissioning and training services. Under the Fair Deal Agreement, Sensus supplies equipment, radiotherapy technologists and clinical oversight in exchange for a contractual percentage of SRT-related reimbursements collected from payors. The company launched Sensus Healthcare Financial Services, a financing program through third-party banks, and Sensus Link, cloud-based software and connectivity for SRT-100 systems, in February 2026.
No SEC Form 4 filings for $SRTS in the last 30 days.
See all $SRTS insider activity →Sensus Healthcare, Inc. (SRTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights Commercial Momentum Builds with Broader Physician Engagement and Customer Adoption New Dermatology Group Relationships Support Customer Expansion and Diversification Strategy Incre
Sensus Healthcare (SRTS) reported Q3 revenue of $6.0M, down 13% YoY. Gross margin improved to 55% from 39.1%, but net loss widened to $1.5M, or $0.09 per share. The company cited higher unit shipments and improved gross margin despite lower revenue and increased net loss.
Sensus Healthcare (SRTS) will report Q3'26 earnings on October 29. Analysts expect revenue of $6.61M and EPS of -$0.06. The announcement is scheduled for 8:00 AM ET.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning SRTS (Sensus Healthcare, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 3 bearish.
Recent SRTS coverage spans insider activity, earnings and financial news.
Earnings miss and higher losses likely weigh on the stock.
Earnings miss and widening loss suggest negative price pressure.
Earnings preview provides limited guidance; market may price in modest expectations.
Insider purchase signals confidence from a board member, but the amount is modest.
Small insider purchase signals confidence but limited market impact.
AlphAI scores every news story that mentions SRTS with an AI model for sentiment and relevance, and aggregates insider trades from Sensus Healthcare, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sensus Healthcare, Inc. (SRTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights Commercial Momentum Builds with Broader Physician Engagement and Customer Adoption New Dermatology Group Relationships Support Customer Expansion and Diversification Strategy Incre
Sensus Healthcare (SRTS) reported Q3 revenue of $6.0M, down 13% YoY. Gross margin improved to 55% from 39.1%, but net loss widened to $1.5M, or $0.09 per share. The company cited higher unit shipments and improved gross margin despite lower revenue and increased net loss.
Sensus Healthcare (SRTS) will report Q3'26 earnings on October 29. Analysts expect revenue of $6.61M and EPS of -$0.06. The announcement is scheduled for 8:00 AM ET.
Sachetta Eric purchased 64,841 shares of Sensus Healthcare, Inc. (SRTS) at an average of $3.48 ($3.44–$3.54, $0.23M total) across 2 trades over 2026-08-28 to 2026-08-31.
Sachetta Eric purchased 20,633 shares of Sensus Healthcare, Inc. (SRTS) at an average of $3.23 ($3.18–$3.29) across 2 trades over 2026-08-26 to 2026-08-27.
Eric Sachetta, a director at Sensus Healthcare (SRTS), bought 34,697 shares for $112,904 at $3.254 per share. He now holds 209,310 shares directly and 2,093 indirectly. SRTS stock rose 16% in the past week but faces profitability challenges. Q2 2026 results missed expectations, with a loss of $0.53 per share and revenue of $2.3M, down 68.5% YoY. Management cited financing delays but expects stronger H2 2026 performance.
Sachetta Eric purchased 34,697 shares of Sensus Healthcare, Inc. (SRTS) at $3.25 ($0.11M total) on 2026-08-24.
Sardano Joseph C (CHIEF EXECUTIVE OFFICER) purchased 20,000 shares of Sensus Healthcare, Inc. (SRTS) at $3.02 on 2026-08-20.
Sachetta Eric purchased 31,000 shares of Sensus Healthcare, Inc. (SRTS) at an average of $3.16 ($3.13–$3.25) across 2 trades over 2026-08-20 to 2026-08-21.
Sensus Healthcare (SRTS) reported Q2 2026 revenue of $2.3M, down 68.5% YoY, due to fewer units sold and delayed financing approvals. Units sold decreased to 11 from 19 in Q2 2025. Gross margin was 34.8%, and net loss was $8.7M. The company expects 20+ units per quarter in Q3 and Q4. Cash reserves decreased to $15.2M. Management criticized a bank for financing delays and plans to focus on recurring revenue models and international expansion.
